東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Benefit-risk assessment of medicines...

Leong, James.

Linked to FindBook

Google Book

Amazon

博客來

Benefit-risk assessment of medicines = the development and application of a universal framework for decision-making and effective communication /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Benefit-risk assessment of medicines/ by James Leong, Sam Salek, Stuart Walker.
Reminder of title:	the development and application of a universal framework for decision-making and effective communication /
Author:	Leong, James.
other author:	Salek, Sam.
Published:	Cham :Springer International Publishing : : 2015.,
Description:	xiii, 317 p. :ill., digital ;24 cm.
[NT 15003449]:	Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.
Contained By:	Springer eBooks
Subject:	Drugs - Testing. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-15805-1
ISBN:	9783319158051 (electronic bk.)

Benefit-risk assessment of medicines = the development and application of a universal framework for decision-making and effective communication /
Leong, James.

Benefit-risk assessment of medicinesthe development and application of a universal framework for decision-making and effective communication /[electronic resource] :by James Leong, Sam Salek, Stuart Walker. - Cham :Springer International Publishing :2015. - xiii, 317 p. :ill., digital ;24 cm.

Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.

Over the past decade pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured systematic standardized approach. In view of this a universal framework together with an appropriate documentation system for recording benefit-risk decisions has been developed and applied and is a valuable addition to the Benefit-Risk Toolbox. The opportunity to examine the implementation of this approach by several regulatory authorities places this book in a unique position with the potential to positively contribute to the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is also reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Therefore, this is not an attempt to provide a comprehensive and complete account of the current benefit-risk assessment environment; rather, the strength of this book is that it provides an evaluation of some current approaches to the benefit-risk assessment of medicines and outlines the development of a new universal framework. It also demonstrates how a number of mature agencies have implemented this universal framework together with the methodology for documenting their benefit-risk decisions. In addition, it also reviews current publicly available documents together with their strengths and weaknesses in communicating benefit-risk decisions to stakeholders.

ISBN: 9783319158051 (electronic bk.)

Standard No.: 10.1007/978-3-319-15805-1doiSubjects--Topical Terms:

646233
Drugs
--Testing.

LC Class. No.: RM301.27

Dewey Class. No.: 615.1901

Benefit-risk assessment of medicines = the development and application of a universal framework for decision-making and effective communication /
LDR:03081nmm m2200313 m 4500 001 2001909
003 DE-He213
005 20151119151708.0
006 m d
007 cr nn 008maaau
008 151215s2015 gw s 0 eng d
020 $a 9783319158051 (electronic bk.)
020 $a 9783319158044 (paper)
024 7 $a 10.1007/978-3-319-15805-1 $2 doi
035 $a 978-3-319-15805-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.27
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.1901 $2 23
090 $a RM301.27 $b .L583 2015
100 1 $a Leong, James. $3 2145879
245 1 0 $a Benefit-risk assessment of medicines $h [electronic resource] : $b the development and application of a universal framework for decision-making and effective communication / $c by James Leong, Sam Salek, Stuart Walker.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a xiii, 317 p. : $b ill., digital ; $c 24 cm.
505 0 $a Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References.
520 $a Over the past decade pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured systematic standardized approach. In view of this a universal framework together with an appropriate documentation system for recording benefit-risk decisions has been developed and applied and is a valuable addition to the Benefit-Risk Toolbox. The opportunity to examine the implementation of this approach by several regulatory authorities places this book in a unique position with the potential to positively contribute to the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is also reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Therefore, this is not an attempt to provide a comprehensive and complete account of the current benefit-risk assessment environment; rather, the strength of this book is that it provides an evaluation of some current approaches to the benefit-risk assessment of medicines and outlines the development of a new universal framework. It also demonstrates how a number of mature agencies have implemented this universal framework together with the methodology for documenting their benefit-risk decisions. In addition, it also reviews current publicly available documents together with their strengths and weaknesses in communicating benefit-risk decisions to stakeholders.
650 0 $a Drugs $x Testing. $3 646233
650 0 $a Pharmaceutical policy $x Decision making. $3 2145882
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Pharmacoeconomics and Health Outcomes. $3 2089175
650 2 4 $a Quality of Life Research. $3 897157
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
700 1 $a Salek, Sam. $3 2145880
700 1 $a Walker, Stuart. $3 2145881
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-15805-1
950 $a Medicine (Springer-11650)